46 related articles for article (PubMed ID: 10854140)
21. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer.
Spicer J; Plunkett T; Somaiah N; Chan S; Kendall A; Bolunwu N; Pandha H
Prostate Cancer Prostatic Dis; 2005; 8(4):364-8. PubMed ID: 16077679
[TBL] [Abstract][Full Text] [Related]
23. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
[TBL] [Abstract][Full Text] [Related]
24. Inverse-electron-demand Diels-Alder reaction as a highly efficient chemoselective ligation procedure: synthesis and function of a BioShuttle for temozolomide transport into prostate cancer cells.
Pipkorn R; Waldeck W; Didinger B; Koch M; Mueller G; Wiessler M; Braun K
J Pept Sci; 2009 Mar; 15(3):235-41. PubMed ID: 19177421
[TBL] [Abstract][Full Text] [Related]
25. Revisiting Temozolomide's role in solid tumors: Old is gold?
Matthaios D; Balgkouranidou I; Neanidis K; Sofis A; Pikouli A; Romanidis K; Pappa A; Karamouzis M; Zygogianni A; Charalampidis C; Zarogoulidis P; Rigas G; Galanis A
J Cancer; 2024; 15(11):3254-3271. PubMed ID: 38817857
[TBL] [Abstract][Full Text] [Related]
26. PARP inhibitor combinations in prostate cancer.
Pezaro C
Ther Adv Med Oncol; 2020; 12():1758835919897537. PubMed ID: 32215055
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of hPMC2 imparts chemotherapeutic sensitivity to alkylating agents in breast cancer cells.
Krishnamurthy N; Liu L; Xiong X; Zhang J; Montano MM
Cancer Biol Ther; 2015; 16(4):518-27. PubMed ID: 25849309
[TBL] [Abstract][Full Text] [Related]
28. Characterization of a novel anti-cancer compound for astrocytomas.
Lee SY; Slagle-Webb B; Rizk E; Patel A; Miller PA; Sung SS; Connor JR
PLoS One; 2014; 9(9):e108166. PubMed ID: 25255031
[TBL] [Abstract][Full Text] [Related]
29. Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.
Hussain M; Carducci MA; Slovin S; Cetnar J; Qian J; McKeegan EM; Refici-Buhr M; Chyla B; Shepherd SP; Giranda VL; Alumkal JJ
Invest New Drugs; 2014 Oct; 32(5):904-12. PubMed ID: 24764124
[TBL] [Abstract][Full Text] [Related]
30. High-resolution flow cytometry: a suitable tool for monitoring aneuploid prostate cancer cells after TMZ and TMZ-BioShuttle treatment.
Braun K; Ehemann V; Wiessler M; Pipkorn R; Didinger B; Mueller G; Waldeck W
Int J Med Sci; 2009 Nov; 6(6):338-47. PubMed ID: 19946604
[TBL] [Abstract][Full Text] [Related]
31. TMZ-BioShuttle--a reformulated temozolomide.
Waldeck W; Wiessler M; Ehemann V; Pipkorn R; Spring H; Debus J; Didinger B; Mueller G; Langowski J; Braun K
Int J Med Sci; 2008 Sep; 5(5):273-84. PubMed ID: 18797509
[TBL] [Abstract][Full Text] [Related]
32. O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts.
Clemons M; Kelly J; Watson AJ; Howell A; McElhinney RS; McMurry TB; Margison GP
Br J Cancer; 2005 Nov; 93(10):1152-6. PubMed ID: 16278661
[TBL] [Abstract][Full Text] [Related]
33. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).
Trudeau ME; Crump M; Charpentier D; Yelle L; Bordeleau L; Matthews S; Eisenhauer E
Ann Oncol; 2006 Jun; 17(6):952-6. PubMed ID: 16565212
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
Bhandari MS; Pienta KJ; Fardig J; Olson K; Smith DC
Cancer; 2006 Apr; 106(8):1715-21. PubMed ID: 16534795
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
36. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
[TBL] [Abstract][Full Text] [Related]
37. A randomised dose-finding phase II study on ifosfamide in metastatic hormone-refractory prostate cancer (HRPC).
Hervonen P; Lehtinen T; Tammela TL; Kellokumpu-Lehtinen P
J Exp Clin Cancer Res; 2002 Jun; 21(2):177-80. PubMed ID: 12148574
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of temozolomide in hormone-refractory prostate cancer.
van Brussel JP; Busstra MB; Lang MS; Catsburg T; Schröder FH; Mickisch GH
Cancer Chemother Pharmacol; 2000; 45(6):509-12. PubMed ID: 10854140
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
